Trial Type
First-Line-Therapy (Metastatic Disease/Hematology)
Description for experts
Venetoclax plus azacitidine versus standard intensive chemotherapy for patients with newly diagnosed acute myeloid leukemia (AML) and NPM1 mutations eligible for intensive treatment
Description for laymen
Venetoclax plus azacitidine versus standard intensive chemotherapy for patients with newly diagnosed acute myeloid leukemia (AML) and NPM1 mutations eligible for intensive treatment
JSON Data
{
"short_title": "VINCENT",
"data_mode": "910",
"data_mode_number": "000000014",
"official_title": null,
"accrual_state": "running",
"therapeutic_value": "not_applicable",
"therapieansatz_value": "not_applicable",
"therapieintervention_value": "not_applicable",
"therapielinie_value": "first",
"ctgov_number": null,
"eudract_number": "2021-003248-26",
"general_contact_email": "sal-aml-register@ukdd.de",
"general_contact_phone": "+49 351-45818380",
"hauptpruefer_dd_name": null,
"description_laie_de": "Venetoclax plus Azacitidin versus intensive Standardchemotherapie in der Behandlung von fitten Patienten mit neu diagnostizierter akuter myeloischer Leuk\u00e4mie (AML) und NPM1 Mutation",
"description_laie_en": "Venetoclax plus azacitidine versus standard intensive chemotherapy for patients with newly diagnosed acute myeloid leukemia (AML) and NPM1 mutations eligible for intensive treatment",
"description_expert_de": "Venetoclax plus Azacitidin versus intensive Standardchemotherapie in der Behandlung von fitten Patienten mit neu diagnostizierter akuter myeloischer Leuk\u00e4mie (AML) und NPM1 Mutation",
"description_expert_en": "Venetoclax plus azacitidine versus standard intensive chemotherapy for patients with newly diagnosed acute myeloid leukemia (AML) and NPM1 mutations eligible for intensive treatment",
"rechtsgrundlage_value": null,
"phase_amg_value": null,
"main_cat_id": 4,
"sub_cat_id": 30
}
